ClinicalTrials.gg
Active, not recruitingNCT06534619Updated Aug 2, 2024

Additional Effects of Joint Mobilization in Addition to Rocabado Exercises on Alleviating Trismus Following Third Molar Extraction

An interventional study of Electrotherapy and Rocabado exercises in Trismus, sponsored by Foundation University Islamabad. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Foundation University Islamabad · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Without appropriate early intervention, prolonged trismus can lead to lasting complications like reduced jaw mobility or temporomandibular joint disorders.Therefore joint mobilization will impact on trismus, that will offer valuable insights into how these interventions will affect inflammation, muscle function and overall healing process within TMJ besides rocabado exercises that involves a series of movements and stretches targeting the muscles and joints involved in chewing,swallowing and speaking and minimizing muscle tension and opening the mouth, preventing further deterioration of jaw function and improving overall quality of life of individuals. If found effective, this will be added to the literature for the treatment of trismus after third molar extraction.

02

Conditions studied

  • Trismus

Browse trials for

03

In context

Trismus

107 studies on the registry are indexed under Trismus; 19 are open to participants now.

This study's planned enrollment of 54 is close to the median of 52 across 99 interventional studies indexed under Trismus.

Browse Trismus studies →

Lead sponsor

Foundation University Islamabad is the lead sponsor of 255 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Referral or consultation from a dentist to confirm the diagnosis of trismus.
  • Age 18-45 years
  • Both genders (Male and Female)
  • Maximal interincisal opening ≤ 35mm (Restricted jaw motion).
  • Unilateral/Bilateral impacted lower third molars.
  • 3 days Post mandibular Third molar extraction

Exclusion criteria

Exclusion Criteria:

  • Local Infection or bleeding post third molar extraction.
  • Patients with Acute pericoronitis
  • Patient undergoing chemotherapy and radiotherapy.
  • Type I diabetes, renal failure and chronic liver disease were excluded as state.
  • Pregnant or lactating women.
  • Cyst or tumor associated with impacted tooth
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Maitland joint mobilization + Rocabdo exercises

    Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 Minutes. Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3. Techniques used are anterior, lateral and inferior glides Frequency: 3-4 times in 1 week . 4 sessions in total.

    Procedure: Electrotherapy · Procedure: Rocabado exercises · Procedure: Maitland oscillatory mobilizations

  • Experimental
    Rocabado exercises

    Participants of this Group will receive the conventional physical therapy along with 6 Rocabado exercises.6 reps each Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 Minutes. Frequency: 3-4 times in 1 week . 4 sessions in total.

    Procedure: Electrotherapy · Procedure: Rocabado exercises

Interventions

  • ProcedureElectrotherapy

    Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.

  • ProcedureRocabado exercises

    6 Rocabado exercises 6 Reps each.

  • ProcedureMaitland oscillatory mobilizations

    Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3. Techniques used are anterior, lateral and inferior glides

06

What researchers measure

Primary outcomes

  1. Pain intensity

    pain will be measured using Numeric pain rating scale

    Time frame: 1 week

  2. Range of motion

    A Vernier caliper will be used to measure maximal incisal opening (MIO) ≤ 35 mm (ROM)

    Time frame: 1 week

  3. Functional Performance

    Gothenburg Trismus Questionnaire will be used for assessing functional performance or trismus-related quality of life.

    Time frame: 1 week

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2024, 6 months after the start.

Of 57 non-industry interventional studies with no phase under Trismus, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 21. This study's planned 6 months is below that.

Counting every sponsor, half of 58 studies reached it within 8 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Dec 10, 2024
CompletionEst.
Dec 30, 2024
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06534619
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Jun 10, 2024
Primary completion
Dec 10, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Aug 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion